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ORIGINAL ARTICLE
Short term outcome and predictors of response to neoadjuvant treatment in
rectal cancer
Rizwan Sultan,1 Tabish Chawla,2 Mirza Aman Beg3

Abstract
Objective: To evaluate response to neoadjuvant chemoradiation in the treatment of rectal cancer and to see if it can
be predicted whether a particular patient will benefit from such treatment.
Methods: The retrospective case series was done at the Aga Khan University Hospital, Karachi, and comprised data
related to period from January 2005 to December 2014 of patients with rectal cancer who had received neoadjuvant
treatment. They were divided into responders and non-responders on the basis of imaging. Pre-treatment factors
were compared to identify differences in the two groups. SPSS 19 was used for statistical analysis.
Results: The median age of 35 patients whose records were studied was 44 years (interquartile range: 33-54).
Response to neoadjuvant treatment was seen in 13(37%) patients with complete pathological response in 8(22.9%).
There was no statistically significant difference in age, gender, pre-treatment tumour stage, tumour biology and
distance from anal verge among the responders and the non-responders (p>0.05 each).
Conclusion: Response to neoadjuvant treatment in rectal cancer was low.
Keywords: Neoadjuvant chemoradiation, Rectal cancer, Karachi. (JPMA 65: 1065; 2015)

Introduction
Rectal cancer is the third most common cancer after lung
and prostate cancers in males, and breast and lung
cancers in females worldwide. In 2009 in the United
States more than 40,000 cases of rectal cancer were
diagnosed.1
Despite histological and behavioural similarities between
rectal and colonic cancers, there are some important
differences. Mesorectum is fat pad surrounding the
rectum, and contains lymphatics and lymph nodes,
separating it from surrounding structures even when
tumour breeches the muscular layer. It remains surgically
resectable when it is within this fat pad. This fat pad is not
present in the rest of the colon. The second difference is
the retroperitoneal location of lower rectum which gives
fixity and, hence, radiation can be used as a treatment
modality. The proximity of sphincter complex leads to
issues related to sacrifice or preservation of continence.
Drainage of lower part of rectum by systemic circulation
rather than mesenteric circulation can result in direct
metastasis to lungs and other sites of the body.
Preoperative staging can be done by endorectal
ultrasound, which has good sensitivity of 87%2 but it is an
invasive test, not readily available and operatordependent. Also, it cannot judge the metastatic nature of
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the disease. The staging can also be done with magnetic
resonance imaging (MRI) or computed tomography (CT)
scan but they have low sensitivity of 77% and 74%.2 They
are non-invasive, non-operator-dependent and provide
information related to metastatic deposits of the disease.
Surgery followed by adjuvant chemotherapy is the
treatment decided on final histopathology staging. The
second option of treatment is neoadjuvant
chemoradiation followed by surgery, which is usually
offered to Stage-3 tumours.
Five-year survival of Stage-I is about 90% when treated
surgically. For Stage II it is 75% when treated surgically. In
Stage III with lymph node metastasis, the five-year
survival is 50%. For Stage IV it is <5%.3
The objective of neoadjuvant treatment is down-staging
of disease, with complete pathological response seen in
10-25% of cases,4-8 sphincter preservation9 for surgically
unresectable tumours, and increased disease-free survival
rate of 30% at 5 years.10,11
The downside of neoadjuvant therapy is chemotherapy
side effects i.e. enteritis and, more seriously, neutropenia,
theoretical possibility of progression of disease in nonresponders, cost of neoadjuvant therapy which is
equivalent to the cost of surgery, especially in a society
where patients have to bear the cost, and no overall
survival.10,11
The question arises; can it be predicted before

1066
neoadjuvant treatment whether a particular patient will
benefit from it or not? As an answer to this question, workup is being done to identify the predictors of response to
neoadjuvant treatment, not only in rectal cancer but in all
other cancers as well. Common work-up variables include
age at diagnosis, gender, tumour biology, distance from
anal verge and immunocytochemical predictors, but to
date there are no definitive set of factors identified for
prediction of good response.
The current study was planned to evaluate the response
of rectal cancer to neoadjuvant treatment in our
population and to compare the characteristics of
responders with non-responders. The secondary
objective was to compare characteristics of patients with
complete radiological response to neoadjuvant treatment
for resectable rectal cancer with those of the nonresponders.

Patients and Methods
The retrospective study was done at the Aga Khan
University Hospital (AKUH), Karachi, and comprised
records related to the period between January 2005 and
December 2014. Records included were of patients over
16 years of age who were diagnosed as surgically
resectable rectal cancer at presentation, and who were
given neoadjuvant treatment, pre-treatment and posttreatment imaging and surgical treatment. The exclusion
criteria was T4 lesions, patients offered upfront surgery,
and those with incomplete or missing records. By using
International Classification of Diseases (ICD) code 153.9,
medical records of colorectal cancer patients were
retrieved.
After histopathological confirmation, pre-treatment
imaging was done, followed by neoadjuvant treatment
for 6 weeks 5 Fluorouracil infusion and concurrent
radiation 5 days a week for 6 weeks. Post-treatment
imaging was done after which the patient underwent
surgery and final histopathological staging was achieved.
Recorded variables included demographics, date of
diagnosis, pre-treatment and post-treatment 'tumour,
node, metastasis' (TNM) as recorded by a consultant
radiologist especially for this study, days from diagnosis to
surgery, surgical procedure, histopathological diagnosis
and histopathological TNM.
Response to neoadjuvant treatment was divided into
three groups on the basis of pre-treatment imaging
compared with post-treatment imaging. The first groups
was Regression Group in which down-staging was
achieved. This group included patients with partial and
complete pathological response. Second was the Static
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Group in which the stage remained the same. There was
also the Progression Group in which there was increase in
the stage of tumour. The study groups were responders
and non-responders. Responders included complete
pathological response plus partial pathological response,
and non-responders included static disease and
progression of disease.
Data analysis was done using SPSS 19. Descriptive analysis
of continuous variables was done with median and
interquartile range (IQR) for skewed variables. Categorical
variables were represented in frequencies and
percentages. Comparative analysis of continuous
variables was done with Mann Whitney U test or one-way
analysis of variance (ANOVA) and that of categorical
variables was done with Fisher Exact Test.

Results
Initially, medical records of 214 patients of colorectal
cancer were retrieved. From these, 115(53.7%) patients
had colonic cancer and 99(46%) had rectal cancer. From
these 99 patients, 35(35.4%) matched the inclusion
criterion, and comprised the stud sample.
The median age of these 35 patients was 44 years
(interquartile range [IQR]: 33-54) and the male-female
ratio was24:11. Overall, 33(94.3%) cases were T3 lesions
and 20(57.1%) were N1. The median distance from anal
verge was 4cm (IQR: 5-3cm). Besides, 12(34.3%) had
Table-1: Baseline characteristics.
Characteristic (n=35)

Frequencies

Age in years (Median)
Gender (male:female)
Tumour
T2
T3
Nodal status
N0
N1
Distance from anal verge in cms(Median)
Histopathology
undifferentiated AdenoCA
mod. differentiated AdenoCA
well differentiated AdenoCA
mucinous AdenoCA
Surgical procedure
LAR
APR
Diagnosis to surgery (days) (Median)

44 (IQR 54-33)
24:11:00
2 (5.7%)
33 (94.3%)
15 (42.9%)
20 (57.1%)
4 (IQR 5-3)
10 (28.6%)
12 (34.3%)
7 (20%)
6 (17.1%)
11 (31.4%)
24 (68.6%)
99 (IQR 110-93)

IQR: Interquartile range
AdenoCA: Adenocarcinoma
LAR: Low Anterior Resection
APR: AbdominoPerineal Resection.
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Table-2: Comparison of factors between Responders and Non-responders.
Factors

Regression (n=13)

Static (n=20)

Progression (n=2)

P value

51.8±13.2

39.6±14.5

41±11.3

0.13*
0.651

10
3

13
7

1
1

2
11

0
20

0
2

6
7

7
13

2
0

3
6
3
1

7
6
2
5

0
0
2
0

Age (years)
Gender
Male
Female
Pre Treatment Tumour
T2
T3
Pre Treatment Nodal status
N0
N1
Histopathology
undiffer. AdenoCA
mod. Diff. AdenoCA
well diff. AdenoCA
mucinous AdenoCA

0.157

0.675

0.25

*One Way ANOVA
AdenoCA: Adenocarcinoma.

Table-3: Comparison betweenpatients with Complete Pathological Response (CPR)
and Noresponse.
Predictive factors

CPR (n=8) Non-responders(n=22) P value

Age (years)
50.5±13.6
Gender
6
Male
2
Female
Pre-treatment Tumour status
1
T2
7
T3
Pre-treatment Nodal status
3
N0
5
N1
Distance from anal verge (Median) 4.6±1.79
Histopathology
undifferentiated AdenoCA
0
mod. differentiated AdenoCA
3
well differentiated AdenoCA
4
mucinous AdenoCA
1
Diagnosis to surgery (days) (Median) 110±32

40.3±13.9
14
8

0.34
0.61

0
22

0.08

10
12

0.76

4.28±1.75

0.656

9
6
2
5
111±40

0.159

0.949

AdenoCA: Adenocarcinoma.

moderately differentiated adenocarcinoma followed by
poorly differentiated adenocarcinoma 10(28.6%). Further,
24(68.6%) patients had abdominoperineal resection (APR)
done as a surgical procedure. Median days from diagnosis
to surgery were 99 days (IQR: 110-93 days) (Table-1).
In terms of outcome, regression of tumour was seen in
13(37.1%) patients; and among them complete
pathological response was seen in 8(22.9%). In 20(57.1%)
Vol. 65, No. 10, October 2015

patients the disease remained static, while progression of
disease was seen in 2(5.7%). There was no statistical
difference between age of patients, tumour status, nodal
status, distance from anal verge and histopathological
diagnosis in both groups (p>0.05 each) (Table-2).
There was no statistical difference between age, pretreatment tumour status, nodal status, distance from anal
verge and histopathological diagnosis in both groups
(Table-3).

Discussion
To summarise, most of patients undergoing neoadjuvant
treatment were T3 (94.3%). The regression of disease was
seen in 37.1% of patients. Complete pathological
response was seen in 22.9% of cases, while 5.2% patients
had progression of the disease. There was no factor found
significant to predict whether a particular patient will
benefit from neoadjuvant treatment for rectal cancer.
Some research work has been done on this topic in the
last few years. The first such study12 included 242 patients
who presented from 1997 to 2007. The intervention was
similar to our study and it saw complete pathological
response of 24%. Another study13 included 562 patients
in 15 years and treatment was 5 Fluorouracil (FU) or
Capecitabine and radiation. The response was 57% and
circumferential involvement of < 60% was predictive for
good response. A study14 included 51 patients from 2005
to 2012. The treatment regimen was slightly different
from ours but it showed regression in 55% cases and in
12% there was complete pathological response. It also
failed to ascertain any predictive factors for this good
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response. In our study we had 35 patients and
intervention was 5FU with radiation. The response was
37.1%, which is lower than rest of the studies, but
complete pathological response is almost equal or better
than the other studies. We were unable to find any
statistically significant factor to predict good response of
treatment.
Our study is the first local research conducted on this
topic, and imaging details were reviewed by a consultant
radiologist.
The limitations of our study are its small sample size,
retrospective nature, and most of the imaging was CT
scanning, which has low accuracy for staging of rectal
cancer.

Conclusion
Response to neoadjuvant treatment was lower in our
population than other populations. Younger patients had
relatively poor response to the treatment than the older
one though it was statistically insignificant. There is need
to study causes of lower response rate in our population.
A prospective study is needed to confirm the findings.
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